Biocon Biologics Ltd. (BBL), a subsidiary of Biocon Ltd., is a fully integrated, global biosimilars company committed to transforming healthcare and transforming lives by enabling affordable access to biosimilars for millions of patients worldwide. It is leveraging cutting-edge science, innovative tech platforms, global scale manufacturing capabilities and world-class quality systems to lower costs of biological therapeutics while improving healthcare outcomes.
Biocon Biologics has a portfolio of ten biosimilars and a pipeline of several biosimilar assets across diabetology, oncology, immunology, ophthalmology, and bone health.
Biocon was founded by Kiran Mazumdar-Shaw, a first-generation entrepreneur who started her biotech business in 1978 in India and built a global business with over 4 decades of experience in biotechnology, contributing to offer accessible and affordable treatments to millions of patients worldwide.
Biocon Biologics was founded in 2019 and today is a fully integrated global biosimilars company with end-to-end capabilities from “lab-to-market” and a broad portfolio.
